Month: April 2015

Why isn’t Cymbalta maker telling us about the aftereffects?

Published on April 29, 2015, by Matthew Sharp

Product Liability

Cymbalta is a much-prescribed drug whose producers have come under scrutiny for allegedly misleading the public through inadequate labeling. Plaintiffs in current cases say that the label does not sufficiently warn patients of the potential for extreme withdrawal symptoms that may occur after missing even a single dose. In broad use The FDA approved the antidepressant Cymbalta, or duloxetine, in 2004, for the treatment of major depressive disorder. In 2007, it was approved for treating general anxiety disorder, and in 2008 for use with patients suffering from fibromyalgia. [...]
+ Continue Reading